LAVAL, Quebec, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. (" Neptune") (Nasdaq:NEPT) (TSX:NTB), the pioneer in the krill oil industry, which holds a vast international patent estate on krill oil compositions and methods of use, reiterates that it achieved its latest patent grant, a continuation patent numbered US 8,278,351 (the "Continuation Patent"), after a thorough examination process. Neptune firmly denies the allegation made by Aker in its press release of October 2, 2012, that Neptune failed to disclose to the U.S. Patent & Trademark Office (the "USPTO") certain record evidence from the re-examination of the '348 patent, another Neptune patent to which the Continuation Patent is related. Not only did Neptune submit all record evidence from this re-examination, but it also submitted approximately 200 references that the USPTO's Examiner reviewed during examination, including all of the references that Aker put forth in requesting re-examination of the '348 patent. Further, as the USPTO record explicitly shows, the USPTO's Examiner was fully aware of the re-examination and considered it before allowing the present patent. "Aker is now facing an action for infringement of a patent that reads directly on its krill oil products and that was allowed over extensive references, including all of the references relied upon by Aker in requesting re-examination of a related Neptune patent," said Benoit Huart, General Counsel of Neptune. "Aker's baseless allegation that Neptune withheld evidence from the USPTO is merely its latest ill-conceived attempt to deflect attention from its infringement of Neptune's patents and diminish Neptune's status as the first and leading innovator in the krill oil industry." About Neptune Technologies & Bioressources Inc. Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.